CPA
MIST icon

Capital Performance Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Capital Performance Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8K Hold
14,756
– – ﹤0.01% 311
2026
Q1 		$17.6K Buy
+14,756
New +$25.8K ﹤0.01% 465

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Capital Performance Advisors's MIST Position: Q2 2026 in Review

Capital Performance Advisors held its Milestone Pharmaceuticals (MIST) position steady in Q2 2026 at 14,756 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #311.

Capital Performance Advisors first reported a position in MIST in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Capital Performance Advisors held 14,756 shares of Milestone Pharmaceuticals worth $19.8K as of Q2 2026.
  • Capital Performance Advisors left its Milestone Pharmaceuticals share count unchanged in Q2 2026.
  • Milestone Pharmaceuticals made up ﹤0.01% of Capital Performance Advisors's portfolio in Q2 2026, its #311 holding.
  • Capital Performance Advisors first reported a position in Milestone Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.